Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).
Country |
1993 |
1994 |
1995 |
1996 |
1997 |
1998 |
1999 |
2000 |
2001 |
2002 |
2003 |
2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Belgium |
|
1.4 |
4.2 |
6.1 |
5.5 |
6.4 |
3.4 |
|
|
|
|
|
|
Czech Republic |
|
|
|
41.2 |
43.2 |
48.8 |
56.8 |
52.8 |
46.0 |
47.8 |
55.0 |
55.6 |
59.0 |
Denmark |
|
|
|
|
|
|
|
11.0 |
7.0 |
|
10.3 |
12.7 |
14.2 |
Germany |
|
|
|
|
|
|
|
|
10.2 |
11.4 |
10.0 |
10.2 |
9.4 |
Greece |
|
|
0.0 |
0.2 |
0.0 |
0.3 |
0.0 |
0.2 |
0.3 |
0.4 |
0.7 |
0.6 |
0.7 |
Spain |
|
|
|
|
1.1 |
1.1 |
2.3 |
2.1 |
2.7 |
3.0 |
3.7 |
|
|
France |
|
|
|
|
|
1.8 |
|
1.6 |
|
|
|
2.1 |
|
Ireland |
|
4.9 |
3.3 |
8.0 |
6.3 |
7.0 |
4.8 |
5.7 |
6.5 |
9.9 |
8.6 |
8.0 |
|
Italy |
|
0.2 |
0.3 |
0.3 |
0.4 |
0.6 |
0.9 |
1.1 |
1.0 |
1.0 |
1.0 |
1.0 |
1.0 |
Cyprus |
|
|
|
|
|
|
|
|
|
6.1 |
6.0 |
6.2 |
5.3 |
Latvia |
|
|
|
|
|
|
|
|
|
|
11.3 |
15.1 |
26.8 |
Lithuania |
|
|
|
|
|
|
|
|
|
|
3.0 |
4.8 |
2.4 |
Luxembourg |
(1) |
|
|
0.0 |
4.0 |
2.0 |
3.0 |
2.0 |
1.0 |
1.0 |
0.0 |
0.0 |
2.5 |
Hungary |
(2) |
|
|
|
7.1 |
12.2 |
14.0 |
10.7 |
7.5 |
7.0 |
6.3 |
8.2 |
9.6 |
Malta |
(3) |
|
|
|
0.8 |
0.4 |
|
|
|
|
|
1.2 |
0.0 |
Netherlands |
|
|
3.5 |
7.2 |
10.3 |
9.5 |
8.1 |
6.7 |
4.8 |
4.1 |
5.6 |
7.0 |
8.3 |
Austria |
(4) |
|
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Poland |
(5) |
|
|
|
|
3.8 |
6.0 |
6.7 |
5.8 |
6.0 |
8.1 |
11.9 |
|
Portugal |
|
|
|
|
|
|
|
0.0 |
0.0 |
|
|
0.8 |
0.5 |
Slovakia |
|
|
1.7 |
1.2 |
2.0 |
2.6 |
3.2 |
2.3 |
6.8 |
7.8 |
15.1 |
25.4 |
32.1 |
Slovenia |
|
|
|
|
|
0.2 |
|
0.7 |
|
|
1.0 |
1.0 |
1.1 |
Finland |
|
|
|
|
|
|
41.1 |
41.9 |
30.8 |
30.0 |
33.9 |
33.9 |
30.9 |
Sweden |
|
|
|
|
|
|
|
|
28.7 |
32.3 |
34.2 |
32.1 |
28.6 |
United Kingdom |
(6) |
11.0 |
9.0 |
10.0 |
9.0 |
9.0 |
9.0 |
8.0 |
4.0 |
3.0 |
3.0 |
6.0 |
7.0 |
Bulgaria |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.2 |
0.9 |
1.5 |
Romania |
|
|
|
|
|
|
|
|
|
0.3 |
0.5 |
1.0 |
1.0 |
Turkey |
|
|
|
|
|
|
|
|
|
|
|
|
7.5 |
Notes: (1) Data refer to all treatments. (2) Data refer to all treatments. For 2004 data refer to first treatments. (3) In order to include time trends, data reported in Table 3 refer to 1 outpatient centre for which data were available for all the time period. (4) Data only refer to clients in substitution treatment, using opioids as primary drug. (5) Data refer to all treatments up to 2002. For 2003 data refers to first treatments. Heroin includes all opioids. For 2004 data was not available therefore not included in the analysis. (6) Data refer to all treatments up to 2002 and to new treatments from 2003. Before 2003 data only refer to amphetamines. See also 'General notes for interpreting data' on the Explanatory notes and help page. Source: 2005 Reitox national reports - Standard Table 4 - First Treatments | |||||||||||||